Participated · Equity · Aug 2026

Network Bio focuses on linking fragmented biorepositories at major academic medical centers to provide trusted, permissioned access to biological samples (blood, tissue), genomic information, and longitudinal clinical data. The company’s work centers on interoperability, standardization, consent management, governance, and privacy-preserving computation to make these assets usable for research, drug discovery, diagnostics, and AI development. Its stated plans include creating federated biological data networks and consent and identity infrastructure that hospitals will trust. Financially, the company recently raised $50 million to advance this infrastructure; the article does not detail other financial metrics, revenue, users, or prior funding rounds. The effort is framed as building an important healthcare AI infrastructure layer by enabling access to high-quality biological samples connected to clinical outcomes.

Participated · Equity · Feb 2026

Big Health builds evidence-based digital therapeutics, most notably SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder, both of which are among just nine FDA-cleared Digital Mental Health Treatments (DMHTs). Its products are delivered directly to patients or through provider partners, integrate into clinical workflows, and are now eligible for national Medicare reimbursement via newly created G-codes. Backed by more than a decade of real-world use, the company reports serving over 750,000 individuals, with clinical studies showing up to 76 % of SleepioRx users and 71 % of DaylightRx users achieving meaningful symptom improvement. Recent partnerships with health systems such as Henry Ford and Northwell signal accelerating adoption. The company positions its digital solutions as scalable, first-line alternatives to pharmaceuticals, addressing the significant care-access gap for the roughly 20 % of U.S. adults with anxiety disorders and the one-third experiencing chronic insomnia. The fresh capital will be used to deepen provider relationships, expand reimbursement pathways, and reach millions more patients.

Led · Series A · Sep 2025

Daymark Health is reengineering the cancer care experience by combining a technology platform with community-based clinicians who deliver navigation, symptom management, mental health services, and social support to patients. The service operates both virtually and in the home, coordinating closely with oncologists and primary care providers to create a seamless, value-based care journey. By contracting directly with health plans, Daymark aligns financial incentives to improve outcomes while lowering the total cost of care. Patients receive 24/7 access to support, which encompasses clinical, social, and mental health needs. The company’s model aims to break down traditional healthcare silos, offering personalized, high-quality oncology care at scale. Fresh capital will be used to expand partnerships with health plans and providers across the United States, bringing the platform to thousands more patients. No operating metrics such as revenue or user counts were disclosed in the article.

Participated · Series C · Sep 2025

Octave Bioscience is a commercial-stage precision care company whose flagship product is the Octave MSDA test, a multi-analyte blood-based assay for monitoring MS disease activity. The company reports broad physician adoption with over 325 prescribers, more than 19,000 patient tests delivered to date, and in-network reimbursement covering over 75 million contracted lives at favorable rates. Proceeds from the recent financings will support continued commercialization of the MSDA test and advancement of the company’s Parkinson’s disease pipeline. Octave describes its platform as providing quantitative, clinically actionable insights to improve disease monitoring and treatment decisions. The company also notes a partnership with the Michael J. Fox Foundation on Parkinson’s disease efforts. Octave is based in Menlo Park, Calif. Octave Bioscience is a commercial-stage precision-medicine company that delivers a Precision Care Solution for multiple sclerosis and other neurodegenerative diseases. Its solution includes the Octave MSDA Test, a multivariate blood test for multiple sclerosis, enhanced MRI analytics and protocols, and a clinical care program that connects patients with MS-certified nurse care partners. The Precision Care Solution is currently in use in over 50 clinics across the United States. Octave plans to expand its biomarker-based approach into Parkinson’s disease and will use a $10M grant from The Michael J. Fox Foundation to discover, develop, and validate a custom multiplexed protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic. The company was selected for the MJFF grant based on its track record in biomarker research and prior commercialization of a multiplexed assay panel for multiple sclerosis. Octave combines blood biomarkers, imaging, and clinical insights to provide longitudinal and holistic patient metrics intended to enable informed care, shared decision making, and better patient outcomes. Octave offers a multimodal precision care solution that combines blood biomarkers, expanded MRI analytics, and clinical insights to objectively measure MS disease activity, progression, and severity. Its platform includes the first multivariate blood test for MS disease activity, enhanced imaging protocols, and a clinical care program linking patients with MS nurse practitioners in real time. Octave commercially launched in late 2022 and is in use at multiple MS Centers of Excellence, academic centers, and high-volume independent clinics. The company is expanding physician partnerships and providing capabilities to pharma companies and health plans. Octave is also committed to building collaborations across a broader range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s. Financially, the company announced a $30M extension to its Series B to accelerate commercialization and broaden patient access to its solution. Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with multiple sclerosis (MS). The platform integrates multiple layers of insight: blood-based biomarkers to assess inflammation and immune modulation, advanced MRI readings and interpretation for CNS-level insights, and real-time symptom tracking via mobile tools, sensors and wearables. All data are integrated into protocols, supported by decision‑support tools and presented in a dashboard that enables individual and population views for better stratification and contextual interventions. Octave plans to use these capabilities to provide measurement and management tools for physicians and precision tools and services for pharmaceutical companies to better characterize therapies and optimize pipeline programs. The company emphasizes longitudinal perspectives on disease progression and aims to expand the platform’s applicability across a broad range of neurodegenerative diseases. Octave is headquartered in Menlo Park, California. Octave Bioscience is completing development of a comprehensive, first-in-class care management platform for neurodegenerative disease, beginning with multiple sclerosis. The platform integrates blood-based biomarkers, enhanced MRI insights, patient monitoring via mobile tools and sensors, and a nurse-led care partner program to produce objective, quantitative measurements. Those measurement layers feed into care pathway models, analytical support systems, decision-support tools and a dashboard to provide longitudinal, population and individual views for clinicians. Octave plans to expand clinical data, initiate early commercial activities, and begin serving neurologists, MS patients and health plans. The company highlights potential application beyond MS to Parkinson’s disease, ALS and Alzheimer’s disease. Octave Bioscience is headquartered in Menlo Park, California.

Participated · Equity · Sep 2025

Noctrix Health is a Pleasanton, CA-based medical device company developing the Nidra Tonic Motor Activation (TOMAC) therapy for Restless Legs Syndrome (RLS). Its flagship TOMAC therapy is a non-pharmacologic treatment intended to reduce symptoms of primary moderate-to-severe RLS and improve sleep quality in adults who are refractory to medications. Led by CEO and President Shri Raghunathan, the company focuses on clinically validated medical technologies to improve quality of life for patients with chronic medical conditions. Noctrix raised up to $33.5M in a financing that included both debt and equity. Backers included Blue Venture Fund and Sandbox Clinical Ventures. The company intends to use the funds to accelerate its U.S. commercial launch. Noctrix Health is a medical device company led by founder and CEO Shri Raghunathan that develops the Nidra™ Tonic Motor Activation (TOMAC) system, a non‑pharmacologic wearable intended to reduce symptoms of primary moderate‑severe Restless Legs Syndrome (RLS). The TOMAC system is designed to improve sleep quality in adults refractory to medications and is available in the US by prescription only. The company closed a $40M Series C financing to advance the therapy toward an anticipated US launch. Noctrix describes itself as committed to developing clinically validated medical technologies that improve quality of life for patients with chronic conditions. The new funding is intended to support regulatory and commercialization activities for the Nidra™ TOMAC therapy in the US.